Home LiteratureArticle Details
PMID: 21969503 Published · ppublish English Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML

Abstract

Recent increases in incidence and survival of oropharyngeal cancers in the United States have been attributed to human papillomavirus (HPV) infection, but empirical evidence is lacking. HPV status was determined for all 271 oropharyngeal cancers (1984-2004) collected by the three population-based cancer registries in the Surveillance, Epidemiology, and End Results (SEER) Residual Tissue Repositories Program by using polymerase chain reaction and genotyping (Inno-LiPA), HPV16 viral load, and HPV16 mRNA expression. Trends in HPV prevalence across four calendar periods were estimated by using logistic regression. Observed HPV prevalence was reweighted to all oropharyngeal cancers within the cancer registries to account for nonrandom selection and to calculate incidence trends. Survival of HPV-positive and HPV-negative patients was compared by using Kaplan-Meier and multivariable Cox regression analyses. HPV prevalence in oropharyngeal cancers significantly increased over calendar time regardless of HPV detection assay (P trend < .05). For example, HPV prevalence by Inno-LiPA increased from 16.3% during 1984 to 1989 to 71.7% during 2000 to 2004. Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 v 20 months; log-rank P < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive (P = .003) but not for HPV-negative patients (P = .18). Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000). If recent incidence trends continue, the annual number of HPV-positive oropharyngeal cancers is expected to surpass the annual number of cervical cancers by the year 2020. Increases in the population-level incidence and survival of oropharyngeal cancers in the United States since 1984 are caused by HPV infection.

MeSH Terms
Adult Aged Carcinoma, Squamous Cell/epidemiology,mortality,virology Female Humans Incidence Male Middle Aged Oropharyngeal Neoplasms/epidemiology,mortality,virology Papillomaviridae/isolation & purification SEER Program United States/epidemiology
Authors & Affiliations
18 authors, click to expand affiliations / ORCID
Chaturvedi Anil K
National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 7072, Rockville, MD 20852, USA. chaturva@mail.nih.gov
Engels Eric A
Pfeiffer Ruth M
Hernandez Brenda Y
Xiao Weihong
Kim Esther
Jiang Bo
Goodman Marc T
Sibug-Saber Maria
Cozen Wendy
Liu Lihua
Lynch Charles F
Wentzensen Nicolas
Jordan Richard C
Altekruse Sean
Anderson William F
Rosenberg Philip S
Gillison Maura L
References (31)
31 references, click to expand
  1. Focus on research: weighing the benefits and costs of HPV vaccination of young men.
    N Engl J Med. 2011 Feb 3;364(5):393-5 PMID: 21288093
  2. The European mesothelioma epidemic.
    Br J Cancer. 1999 Feb;79(3-4):666-72 PMID: 10027347
  3. Herpes simplex virus type 2 in the United States, 1976 to 1994.
    N Engl J Med. 1997 Oct 16;337(16):1105-11 PMID: 9329932
  4. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer.
    Int J Cancer. 2006 Dec 1;119(11):2620-3 PMID: 16991119
  5. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.
    J Clin Oncol. 2008 Feb 1;26(4):612-9 PMID: 18235120
  6. Assessment of human papillomavirus in lung tumor tissue.
    J Natl Cancer Inst. 2011 Mar 16;103(6):501-7 PMID: 21293027
  7. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    N Engl J Med. 2007 May 10;356(19):1928-43 PMID: 17494926
  8. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
    BMJ. 2009 Oct 08;339:b3884 PMID: 19815582
  9. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.
    J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 PMID: 10601378
  10. Case-control study of human papillomavirus and oropharyngeal cancer.
    N Engl J Med. 2007 May 10;356(19):1944-56 PMID: 17494927
  11. Two-week versus six-month sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort.
    PLoS One. 2010 Jul 30;5(7):e11918 PMID: 20689835
  12. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.
    J Clin Oncol. 2006 Dec 20;24(36):5630-6 PMID: 17179101
  13. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer.
    J Natl Cancer Inst. 2004 Mar 17;96(6):449-55 PMID: 15026470
  14. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.
    J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 PMID: 18334711
  15. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.
    J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 PMID: 14652239
  16. Health and economic implications of HPV vaccination in the United States.
    N Engl J Med. 2008 Aug 21;359(8):821-32 PMID: 18716299
  17. Predicting the future burden of cancer.
    Nat Rev Cancer. 2006 Jan;6(1):63-74 PMID: 16372017
  18. The economic burden of noncervical human papillomavirus disease in the United States.
    Am J Obstet Gynecol. 2008 May;198(5):500.e1-7 PMID: 18455524
  19. Human papillomavirus and survival of patients with oropharyngeal cancer.
    N Engl J Med. 2010 Jul 1;363(1):24-35 PMID: 20530316
  20. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C.
    Head Neck. 2009 Nov;31(11):1393-422 PMID: 19787782
  21. Cigarette smoking among adults--United States, 2006.
    MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1157-61 PMID: 17989644
  22. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.
    J Clin Oncol. 2008 Jul 1;26(19):3128-37 PMID: 18474878
  23. Age-related crossover in breast cancer incidence rates between black and white ethnic groups.
    J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14 PMID: 19066264
  24. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.
    JAMA. 2006 Aug 23;296(8):964-73 PMID: 16926356
  25. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003.
    Cancer. 2008 Nov 15;113(10 Suppl):2901-9 PMID: 18980273
  26. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
    J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 PMID: 18270337
  27. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
    N Engl J Med. 2011 Feb 3;364(5):401-11 PMID: 21288094
  28. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection.
    J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 PMID: 9811312
  29. Tissues from population-based cancer registries: a novel approach to increasing research potential.
    Hum Pathol. 2005 Jul;36(7):812-20 PMID: 16084952
  30. Condyloma acuminatum - United States, 1966-1981.
    MMWR Morb Mortal Wkly Rep. 1983 Jun 17;32(23):306-8 PMID: 6406818
  31. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer.
    J Natl Cancer Inst. 2007 Dec 5;99(23):1801-10 PMID: 18042931
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
Published
2011-11-10
Epub
2011-00-03
Pages
4294-301
Language
English
Region
United States
NLM ID
8309333
PMCID
PMC3221528
Subset
IM
Grants
Intramural NIH HHS · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com